CureVac N.V. 5CV.F Stock
CureVac N.V. Price Chart
CureVac N.V. 5CV.F Financial and Trading Overview
CureVac N.V. stock price | 2.4 EUR |
Previous Close | 9.05 EUR |
Open | 9.18 EUR |
Bid | 9.04 EUR x N/A |
Ask | 9.11 EUR x N/A |
Day's Range | 9 - 9.18 EUR |
52 Week Range | 5.3 - 15.23 EUR |
Volume | 2.24K EUR |
Avg. Volume | 9.19K EUR |
Market Cap | 2.03B EUR |
Beta (5Y Monthly) | 2.869236 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.47 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 72.97 EUR |
5CV.F Valuation Measures
Enterprise Value | 1.56B EUR |
Trailing P/E | N/A |
Forward P/E | 1.14628 |
PEG Ratio (5 yr expected) | 0.19 |
Price/Sales (ttm) | 40.553547 |
Price/Book (mrq) | 2.8522122 |
Enterprise Value/Revenue | 31.068 |
Enterprise Value/EBITDA | -6.886 |
Trading Information
CureVac N.V. Stock Price History
Beta (5Y Monthly) | 2.869236 |
52-Week Change | -30.068% |
S&P500 52-Week Change | 20.43% |
52 Week High | 15.23 EUR |
52 Week Low | 5.3 EUR |
50-Day Moving Average | 7.6 EUR |
200-Day Moving Average | 7.91 EUR |
5CV.F Share Statistics
Avg. Volume (3 month) | 9.19K EUR |
Avg. Daily Volume (10-Days) | 9.54K EUR |
Shares Outstanding | 223.85M |
Float | 122.9M |
Short Ratio | N/A |
% Held by Insiders | 45.44% |
% Held by Institutions | 24.43% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -478.10% |
Gross Margin | -183.74% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -14.99% |
Return on Equity (ttm) | -41.97% |
Income Statement
Revenue (ttm) | 50.18M EUR |
Revenue Per Share (ttm) | 0.26 EUR |
Quarterly Revenue Growth (yoy) | -70.79% |
Gross Profit (ttm) | -91549000 EUR |
EBITDA | -226372992 EUR |
Net Income Avi to Common (ttm) | -291355008 EUR |
Diluted EPS (ttm) | -1.51 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 617.52M EUR |
Total Cash Per Share (mrq) | 2.76 EUR |
Total Debt (mrq) | 41.15M EUR |
Total Debt/Equity (mrq) | 5.77 EUR |
Current Ratio (mrq) | 7.607 |
Book Value Per Share (mrq) | 3.187 |
Cash Flow Statement
Operating Cash Flow (ttm) | -249252000 EUR |
Levered Free Cash Flow (ttm) | -298620256 EUR |
Profile of CureVac N.V.
Country | Germany |
State | N/A |
City | Tübingen |
Address | Friedrich-Miescher-Strasse 15 |
ZIP | 72076 |
Phone | 49 7071 9883 0 |
Website | https://www.curevac.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 904 |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Q&A For CureVac N.V. Stock
What is a current 5CV.F stock price?
CureVac N.V. 5CV.F stock price today per share is 2.4 EUR.
How to purchase CureVac N.V. stock?
You can buy 5CV.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CureVac N.V.?
The stock symbol or ticker of CureVac N.V. is 5CV.F.
Which industry does the CureVac N.V. company belong to?
The CureVac N.V. industry is Biotechnology.
How many shares does CureVac N.V. have in circulation?
The max supply of CureVac N.V. shares is 255.29M.
What is CureVac N.V. Price to Earnings Ratio (PE Ratio)?
CureVac N.V. PE Ratio is now.
What was CureVac N.V. earnings per share over the trailing 12 months (TTM)?
CureVac N.V. EPS is -1.47 EUR over the trailing 12 months.
Which sector does the CureVac N.V. company belong to?
The CureVac N.V. sector is Healthcare.